Skip to main content
. 2016 Jul 8;5(2):105–116. doi: 10.2217/lmt-2016-0010

Table 2. . Design and patient characteristics of identified studies.

Study Patients Previous treatment Treatments Efficacy and safety outcomes QoL assessment Ref.

      Experimental arm Control arm OS (months) PFS (months) Tolerability (most common adverse events) Scale Frequency of assessment Outcomes  
LUME-Lung 1 Unselected stage IIIB/IV NSCLC (all histologies) Chemotherapy Docetaxel + nintedanib Docetaxel + placebo 12.6 vs 10.3; p = 0.0359 (key secondary end point in adenocarcinoma patients) 3.4 vs 2.7; p = 0.0019 Grade ≥3: diarrhea (3.6 vs 2.6%); reversible increased ALT
(7.8 vs 0.9%; reversible increased ALT (3.4 vs 0.5%)
EORTC QLQ-LC13, EORTC QLQ-C30, EQ-5D and EQ-VAS Baseline, end of every cycle, and end of therapy and at the first follow-up visit TTD (first appearance of a minimal clinically important difference [≥10-point change]) and longitudinal assessment of cough, dyspnea and pain [4,17]

CheckMate 017 Stage IIIB/IV NSCLC (squamous cell histology) Prior systemic therapies Nivolumab Docetaxel 9.2 vs 6.0; p < 0.001 (primary end point) 3.5 vs 2.8; p < 0.001 Grade 3–4: neutropenia (0 vs 30%) LCSS (ASBI and 3-Item Index), EQ-5D and EQ-VAS Baseline, every 4 weeks (nivolumab arm) and every 3 weeks (docetaxel arm) for first 6 months TTD, mean change in scores over time, LCSS ASBI improvement (≥10-point change) by week 12 [13,16]

BR.21 Unselected NSCLC (all histologies) Chemotherapy (one or two lines) Erlotinib Placebo 6.7 vs 4.7; p < 0.001 (primary end point) 2.2 vs 1.8; p < 0.001 All grades: rash (76 vs 17%); anorexia (69 vs 56%); stomatitis (19 vs 3%) EORTC QLQ-LC13, EORTC QLQ-C30 Baseline, every 4 weeks during treatment, 4 weeks after completing treatment and every 12 weeks thereafter until documentation of PD TTD (first appearance of a minimal clinically important difference [≥10-point change]), cough, dyspnea and pain (primary outcome for QoL)
Percentage improved/stable/worse
[18,19]

JMEI Advanced NSCLC (all histologies) Chemotherapy Pemetrexed Docetaxel 8.3 vs 7.9; p = NS (primary end point) 2.9 vs 2.9 Grade 3–4: neutropenia (5 vs 40%); febrile neutropenia (2 vs 13%) LCSS (ASBI) NR Percentage of patients who were improved, stable or worse (or meaningful change) on ASBI (>0.5 SD change from baseline) or LCSS (1-point change) [20,21]

TITAN Advanced NSCLC (all histologies) Platinum-based therapy Erlotinib Docetaxel/pemetrexed 5.3 vs 5.5; p = 0.73 (primary end point) 6.3 vs 8.6; p = 0.089 All grades: rash (50 vs 5%); diarrhea (18 vs 2%); alopecia (0 vs 11%) FACT-L, version 4 Baseline, every 3 weeks until Week 48 and every 12 weeks thereafter until PD TTP
TTD
[22]

TAILOR Advanced, EGFR wild-type NSCLC (all histologies) Platinum-based therapy Erlotinib Docetaxel 5.4 vs 8.2; p = 0.05 (primary end point) 2.4 vs 2.9; p = 0.02 Grade 3–4: low absolute neutrophil count (0 vs 20%); skin toxic effects (14 vs 0%) and asthenia (6 vs 10%) EORTC QLQ-LC13, EORTC QLQ-C30 Baseline and before each treatment cycle [14,15]

TAX-317 Advanced IIIB/IV NSCLC (all histologies) Chemotherapy Docetaxel Best supportive care 7.0 vs 4.6; p = 0.047 (primary end point) TTP (weeks): 10.6 vs 6.7; p < 0.001 Grade 3 or 4 neutropenia: 86% (100 mg/m2) and 67% (75 mg/m2) LCSS
EORTC QLQ-LC13
Baseline, immediately before each treatment cycle, at the end of drug treatment and every 2 months during follow-up Longitudinal analysis; mixed-model analysis and ANCOVA [23,24]

ANCOVA: Analysis of covariance; ASBI: Average symptom burden index; EORTC: European Organization for Research and Treatment of Cancer; EORTC QLQ-C30: EORTC multidimensional core questionnaire; EORTC QLQ-LC13: EORTC lung cancer questionnaire; EQ-5D: EuroQol-5D; EQ-VAS: EuroQol-visual analog scale; FACT-L: Functional Assessment of Cancer Therapy - Lung; LCSS: Lung Cancer Symptom Scale; NR: Not reported; NS: Not significant; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; QoL: Quality of life; RR: Relative risk; SD: Standard deviation; TTD: Time to deterioration; TTP: Time to progression.